Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257693 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
A Phase 1 study of Prostate Adenocarcinoma, sponsored by Alessa Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 7
- Study locations
NCT06257693: Recruiting Phase 1 study of Prostate Adenocarcinoma, sponsored by Alessa Therapeutics.
NCT06257693 is a Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by Alessa Therapeutics. The registered enrollment target is 56 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (74% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06257693, a Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Alessa Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Primary Outcome
Using Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).
Conditions Studied
Interventions
- DRUG enzalutamide
Study Locations (7)
Illinois
- Northwestern University - Chicago
Louisiana
- Mary Bird Cancer Center - Metairie
Maryland
- National Institutes of Health Clinical Center - Bethesda
Oregon
- VA Portland Health Care System - Portland
South Carolina
- Atlantic Urology Specialists - Myrtle Beach
Virginia
- Virginia Commonwealth University - Richmond
Wisconsin
- Aurora Urology - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2028-08-30 |
| Phase | Phase 1 |
What NCT06257693 shows while recruiting
NCT06257693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which enzalutamide is the first listed.
NCT06257693 lists 7 locations in 7 states (Illinois, Louisiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT06257693 about?
NCT06257693 is a clinical study titled "Enzalutamide Implants (Enolen) in Patients With Prostate Cancer". The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
What is the current status of trial NCT06257693?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-06-21. Estimated completion is 2028-08-30.
What conditions does trial NCT06257693 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06257693?
The interventions under investigation include: enzalutamide (DRUG).
Who is sponsoring clinical trial NCT06257693?
This trial is sponsored by Alessa Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06257693 being conducted?
This trial has 7 study locations across Illinois, Louisiana, Maryland, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06257693's enrollment target sits among peer trials
56 60th of 99 higher than 40 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
PSMA PET Response Guided SabR in High Risk Pca
RECRUITING · Phase 1
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
RECRUITING · Phase 1
-
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
RECRUITING · Phase 1
-
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI